|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM13 |
Gene summary for TRIM13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM13 | Gene ID | 10206 |
| Gene name | tripartite motif containing 13 | |
| Gene Alias | CAR | |
| Cytomap | 13q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | L7MTJ6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10206 | TRIM13 | LZE4T | Human | Esophagus | ESCC | 5.08e-07 | 3.06e-01 | 0.0811 |
| 10206 | TRIM13 | LZE7T | Human | Esophagus | ESCC | 2.24e-07 | 2.85e-01 | 0.0667 |
| 10206 | TRIM13 | LZE8T | Human | Esophagus | ESCC | 6.86e-05 | 2.41e-01 | 0.067 |
| 10206 | TRIM13 | LZE20T | Human | Esophagus | ESCC | 3.35e-04 | 9.89e-02 | 0.0662 |
| 10206 | TRIM13 | LZE22T | Human | Esophagus | ESCC | 7.15e-06 | 2.70e-01 | 0.068 |
| 10206 | TRIM13 | LZE24T | Human | Esophagus | ESCC | 2.81e-11 | 3.01e-01 | 0.0596 |
| 10206 | TRIM13 | LZE21T | Human | Esophagus | ESCC | 5.07e-05 | 2.56e-01 | 0.0655 |
| 10206 | TRIM13 | P1T-E | Human | Esophagus | ESCC | 4.91e-08 | 4.75e-01 | 0.0875 |
| 10206 | TRIM13 | P2T-E | Human | Esophagus | ESCC | 1.71e-23 | 4.66e-01 | 0.1177 |
| 10206 | TRIM13 | P4T-E | Human | Esophagus | ESCC | 3.87e-09 | 2.08e-01 | 0.1323 |
| 10206 | TRIM13 | P5T-E | Human | Esophagus | ESCC | 4.77e-05 | 1.50e-01 | 0.1327 |
| 10206 | TRIM13 | P8T-E | Human | Esophagus | ESCC | 9.83e-21 | 2.79e-01 | 0.0889 |
| 10206 | TRIM13 | P9T-E | Human | Esophagus | ESCC | 1.63e-10 | 2.79e-01 | 0.1131 |
| 10206 | TRIM13 | P10T-E | Human | Esophagus | ESCC | 3.09e-25 | 4.18e-01 | 0.116 |
| 10206 | TRIM13 | P11T-E | Human | Esophagus | ESCC | 1.42e-10 | 2.97e-01 | 0.1426 |
| 10206 | TRIM13 | P12T-E | Human | Esophagus | ESCC | 7.44e-32 | 5.70e-01 | 0.1122 |
| 10206 | TRIM13 | P15T-E | Human | Esophagus | ESCC | 1.72e-20 | 4.83e-01 | 0.1149 |
| 10206 | TRIM13 | P16T-E | Human | Esophagus | ESCC | 4.01e-34 | 5.24e-01 | 0.1153 |
| 10206 | TRIM13 | P20T-E | Human | Esophagus | ESCC | 1.14e-16 | 3.03e-01 | 0.1124 |
| 10206 | TRIM13 | P21T-E | Human | Esophagus | ESCC | 5.82e-21 | 2.47e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
| GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
| GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
| GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:003650315 | Esophagus | ESCC | ERAD pathway | 82/8552 | 107/18723 | 5.80e-11 | 1.84e-09 | 82 |
| GO:001624114 | Esophagus | ESCC | regulation of macroautophagy | 102/8552 | 141/18723 | 1.09e-10 | 3.27e-09 | 102 |
| GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM13 | SNV | Missense_Mutation | novel | c.454N>C | p.Phe152Leu | p.F152L | O60858 | protein_coding | tolerated(1) | benign(0.194) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM13 | SNV | Missense_Mutation | novel | c.563N>G | p.Phe188Cys | p.F188C | O60858 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM13 | SNV | Missense_Mutation | novel | c.308N>G | p.Gln103Arg | p.Q103R | O60858 | protein_coding | deleterious(0.01) | probably_damaging(0.91) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
| TRIM13 | SNV | Missense_Mutation | novel | c.843G>A | p.Met281Ile | p.M281I | O60858 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TRIM13 | SNV | Missense_Mutation | c.1159N>A | p.Glu387Lys | p.E387K | O60858 | protein_coding | tolerated_low_confidence(0.22) | benign(0.003) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TRIM13 | insertion | Frame_Shift_Ins | novel | c.459_460insGATCCACGGGTTTTGCCTTGCTCCCACAACTTCTGCAAAA | p.Thr154AspfsTer30 | p.T154Dfs*30 | O60858 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| TRIM13 | insertion | Frame_Shift_Ins | novel | c.568_569insC | p.Glu190AlafsTer13 | p.E190Afs*13 | O60858 | protein_coding | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TRIM13 | insertion | Nonsense_Mutation | novel | c.681_682insCTCTCAACATTTTCTGCCTGACTGATATGCAGCTGATTTGTGGG | p.Ile228LeufsTer7 | p.I228Lfs*7 | O60858 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TRIM13 | insertion | Frame_Shift_Ins | novel | c.575_576insGTGGG | p.Gln193TrpfsTer20 | p.Q193Wfs*20 | O60858 | protein_coding | TCGA-AO-A03L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| TRIM13 | deletion | Frame_Shift_Del | c.1207_1208delNN | p.Phe403CysfsTer5 | p.F403Cfs*5 | O60858 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |